Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGR | P06401 | 7/20 | 0.33 |
| ▸ | NR3C1 | P04150 | 3/20 | 0.33 |
| ▸ | NR3C2 | P08235 | 3/20 | 0.33 |
| ▸ | AR | P10275 | 3/20 | 0.33 |
| ▸ | PNMT | P11086 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12763788 | 0.82 | KDM4E (0.34) | PGRNR3C1NR3C2ARPNMT | |
| SCHEMBL13515593 | 0.80 | PGR (0.33) | PGRNR3C1NR3C2ARPNMT | |
| SCHEMBL25719812 | 0.76 | — | — | |
| SCHEMBL13620942 | 0.72 | — | — | |
| SCHEMBL16020334 | 0.72 | — | — | |
| SCHEMBL24137455 | 0.68 | — | — | |
| SCHEMBL2065243 | 0.68 | — | — | |
| SCHEMBL22091075 | 0.68 | — | — | |
| SCHEMBL25699160 | 0.68 | PGR (0.36) | PGRNR3C1NR3C2AR | |
| SCHEMBL16020339 | 0.67 | GAA (0.36) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230183214-A1 | IL4I1 INHIBITORS AND METHODS OF USE | MERCK SHARP & DOHME LLC | 2023-06-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230183214-A1 | IL4I1 INHIBITORS AND METHODS OF USE | IL4I1, IL4, IL2 | PGR 4235/4885NR3C1 385/4885NR3C2 197/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.